MRK · News · 20260815N
Regulatory Risk
Merck & Co., Inc. · 2026-08-15 · Importance 40 · Surprise 42 · In source text
Third-party reporting identifies the upcoming patent expiration of Merck’s Keytruda as a risk to the company’s long-term outlook. The report does not specify the applicable jurisdiction, expiration date, or estimated revenue exposure. It also highlights Merck’s reliance on Keytruda, without providing a quantified impact on revenue or assets.
Key facts
- The news digest states there is an upcoming patent expiration of Merck's key drug Keytruda, presented as a risk to the company. source
- Richard R. DeLuca sold 45,320 shares of Merck common stock for approximately $5.9 million between August 10 and August 12, 2026. source
- After the August 10–12, 2026 transactions, Richard R. DeLuca directly owns 110,167.07 shares of Merck. source
- The news digest reports insider selling as a risk to Merck. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | The news digest states there is an upcoming patent expiration of Merck's key drug Keytruda, presented as a risk to the company. |